
Phase 3 Data Back Tau PET Agent Florquinitau F 18 for Detecting Neurofibrillary Tangles in Alzheimer Disease
Key Takeaways
- Florquinitau F 18, an 18F-labeled tau radiotracer, is indicated to visualize aggregated tau NFTs in adults evaluated for Alzheimer disease, not for non-Alzheimer tauopathies.
- Two phase 3 studies (617 scans) used an amyloid-PET–informed reference standard to include early symptomatic cases, rather than relying solely on autopsy-confirmed truth standards.
In 2 pivotal phase 3 studies, all 5 readers hit sensitivity and specificity targets for florquinitau F 18 tau PET, including in patients with early symptomatic Alzheimer disease.
Lantheus Holdings has announced results from 2 pivotal phase 3 studies of florquinitau F 18 injection (Tauklarify), a tau PET imaging agent also known as MK-6240. In both studies, all 5 independent readers met the prespecified coprimary end points of sensitivity and specificity. The data supported the Tauklarify’s FDA-approved use and were presented at the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 meeting in Boston, Massachusetts.1
Florquinitau F 18 is a fluorine 18–labeled radiotracer that binds aggregated tau. This lets PET imaging show tau neurofibrillary tangle (NFT) pathology in the brain. It is indicated for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer disease, to identify patients with tau NFT pathology. Its safety and effectiveness have not been established for evaluating non-Alzheimer tauopathies.
The 2 studies evaluated a combined 617 florquinitau F 18 PET scans drawn from 3 established prospective Alzheimer disease studies. To include people with early symptomatic disease, the investigators used a prospectively defined clinical and radiographic reference standard informed by neuropathologic evidence, rather than relying only on autopsy confirmation. Under this standard, amyloid beta PET–positive individuals with cognitive impairment were classified as having tau pathology. Age-matched amyloid beta–negative, cognitively normal individuals were classified as not having tau pathology. Independent reader assessments were then compared against this standard.
"Tau neurofibrillary tangles are among the pathological features most closely associated with cognitive decline and prognosis in Alzheimer disease, making their reliable detection especially important in earlier clinical stages," said Christopher Rowe, MD BMBS, FRACP, FAANMS, the director of Molecular Imaging Research at Austin Health and presenting author of the CTAD presentation. "I am encouraged by the strength and consistency of these findings across both phase 3 studies which clearly show how tau-targeted PET imaging can help identify tau pathology in people with Alzheimer disease, including those in earlier clinical stages of the disease. These findings may give clinicians a clearer view of disease progression at a time when that information may be particularly valuable."
Phase 3 Data
Study success required at least the same 3 of 5 readers to reach a lower bound of the 95% CI above 60% for both sensitivity and specificity. Every reader cleared that bar in both studies.
In Study CE-20-01 (N=279), sensitivity across readers ranged from 79.9% to 88.5%, and specificity ranged from 97.9% to 99.3%. Majority-read sensitivity was 87.8%, and majority-read specificity was 98.6%. Positive predictive value (PPV) was 98.4%, and negative predictive value (NPV) was 89.0%.
In Study CE-23-01 (N=338), sensitivity across readers ranged from 68.2% to 82.4%, and specificity ranged from 93.5% to 99.4%. Majority-read sensitivity was 78.8%, majority-read specificity was 99.4%, PPV was 99.3%, and NPV was 82.3%.
Readers agreed closely with one another in both studies, with generalized Fleiss κ values of 0.92 in CE-20-01 and 0.86 in CE-23-01.
Safety Profile
Safety was assessed in a pooled analysis of 1734 participants from the US POINTER and AIBL studies who received at least 1 dose of florquinitau F 18. The company reported the tracer was generally well tolerated. The most common treatment-emergent adverse events were headache (0.7%), nausea (0.2%), dizziness (0.1%), injection site reactions (0.1%), and abdominal discomfort (0.1%). There are no contraindications. Like other radiopharmaceuticals, the agent adds to a patient’s long-term cumulative radiation exposure.
"What makes these studies particularly noteworthy is the use of a prospectively defined clinical radiological reference standard informed by extensive neuropathological evidence," said Ludger Dinkelborg, PhD, the head of research & development at Lantheus. "This innovative approach allowed the inclusion of images from individuals at the early stages of symptomatic Alzheimer’s disease, and through a rigorous evaluation, demonstrated that the diagnostic performance of Tauklarify PET scans in this population was highly consistent across 2 independent pivotal studies. These findings reinforce how tau imaging, alongside amyloid beta imaging, may provide complementary insights that help researchers better characterize Alzheimer disease and advance hope for physicians and patients fighting against this disease."
The prescribing information includes a warning about the risk of misdiagnosis. Diagnostic performance was established in groups expected to have either mostly no tau pathology or mostly clinically significant tau pathology, so performance may be lower in patients at earlier stages of the pathological spectrum. A negative scan does not necessarily exclude tau NFT pathology, and a positive scan does not necessarily confirm it. Additional evaluation should be considered when clinical uncertainty remains.
Florquinitau F 18 joins flortaucipir F 18 (Tauvid), which the FDA approved in 2020, as a tau PET option for clinicians evaluating patients with cognitive impairment.2
References
1. Lantheus announces pivotal phase 3 results for TAUKLARIFY (florquinitau F 18 injection) PET imaging presented at CTAD 2026. News release. November 16, 2026. Accessed November 17, 2026.
2. Jie CVML, Treyer V, Schibil R, Mu L.
Related to this article








